Skip to main content
Signal8
Launch Terminal

Pacira BioSciences, Inc. (PCRX)

Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.

Sector: Pharmaceutical Preparations

Industry: Drug Manufacturers - Specialty & Generic

Pacira BioSciences, Inc. logo

Pacira BioSciences, Inc.

NASDAQ:PCRXHealthcare
+0.00%$36.39
AH$36.39+0.00%vs close
Mkt Cap$1.45B
Float38.17M
O/S39.91M
Vol
$ Vol
RVOL
Inst Own-
SI11.2%
Earnings
Dilution
Pacira BioSciences, Inc. logoNASDAQ:PCRX$36.39+0.00%
Phase Distribution
102 lead-sponsored trials·6 active·73 completed
Phase 115
Phase 1/22
Phase 221
Phase 2/34
Phase 319
Phase 423
Not applicable18
(50 more as collaborator)
Status Overview
Recruiting3
Active, not recruiting3
Completed73
Stopped22
Unknown1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 4
    Completed

    DepoCyt Therapy in Patients With Neoplastic Meningitis From Lymphoma or a Solid Tumor

    Intrathecal (injected into the spinal fluid) DepoCyt, Intrathecal methotrexate

    Meningeal Neoplasms

    Enrollment
    100
    Start
    Apr 2001
    Primary Completion
    -
    Completion
    Nov 2004
    NCT00029523
  • Phase 4
    Terminated

    A Health Economic Trial in Adult Patients Undergoing Open Colectomy MA402S23B301

    morphine sulfate, bupivacaine liposome extended-release injectable suspension

    Bowel Obstruction

    Enrollment
    2
    Start
    Mar 2012
    Primary Completion
    Jul 2012
    Completion
    Jul 2012
    NCT01507220
  • Phase 4
    Terminated

    A Health Economic Trial in Adult Patients Undergoing Open Colectomy MA402S23B302

    IV morphine sulfate, EXPAREL (bupivacaine liposome injectable suspension)

    Bowel Obstruction

    Enrollment
    5
    Start
    May 2012
    Primary Completion
    Jul 2012
    Completion
    Jul 2012
    NCT01507233
  • Phase 4
    Completed

    Adult Patients Undergoing Open Colectomy MA402S23B303

    IV morphine sulfate, EXPAREL (bupivacaine liposome injectable suspension)

    Bowel Obstruction

    Enrollment
    42
    Start
    Dec 2011
    Primary Completion
    Jul 2012
    Completion
    Aug 2012
    NCT01507246
  • Phase 4
    Completed

    A Health Economic Trial in Adult Patients Undergoing Ileostomy Reversal MA402S23B501

    Group 1 Standard of Care, Group 2 EXPAREL

    Retraction of Colostomy

    Enrollment
    47
    Start
    Mar 2012
    Primary Completion
    Oct 2012
    Completion
    Oct 2012
    NCT01509638
  • Phase 4
    Completed

    A Health Economic Trial in Adult Patients Undergoing Ileostomy Reversal MA402S23B504

    IV morphine sulfate or Sponsor-approved equivalent, EXPAREL

    Retraction of Colostomy

    Enrollment
    33
    Start
    Jan 2012
    Primary Completion
    Oct 2012
    Completion
    Oct 2012
    NCT01509807
  • Phase 4
    Completed

    TAP-patients With Robotic Assisted Lap Prostatectomy

    EXPAREL 20 mL, EXPAREL 40 mL

    Postsurgical Pain, Analgesia +1

    Enrollment
    24
    Start
    Mar 2012
    Primary Completion
    May 2012
    Completion
    Jul 2012
    NCT01582477
  • Phase 4
    Completed

    Study of EXPAREL in Patients Undergoing Breast Augmentation

    Instillation - EXPAREL, Infiltration - EXPAREL

    Mammoplasty, Postoperative Pain

    Enrollment
    19
    Start
    Apr 2012
    Primary Completion
    Nov 2012
    Completion
    Nov 2012
    NCT01582490
  • Phase 4
    Completed

    EXPAREL Infiltrated Into the TAP for Postoperative Analgesia in Unilateral Abdominal Hernia Repair

    EXPAREL

    Hernia

    Enrollment
    13
    Start
    Apr 2012
    Primary Completion
    Dec 2012
    Completion
    Dec 2012
    NCT01801124
  • Phase 4
    Terminated

    EXPAREL Administered by Infiltration Into the TAP for Prolonged Postsurgical Analgesia in Lower Abdominal Surgeries

    EXPAREL, Placebo

    Pain

    Enrollment
    67
    Start
    Aug 2013
    Primary Completion
    Dec 2013
    Completion
    Feb 2014
    NCT01919190
  • Phase 4
    Terminated

    EXPAREL Administered Into the TAP for Analgesia in Subjects Undergoing Open Total Abdominal Hysterectomy

    EXPAREL

    Postoperative Pain

    Enrollment
    1
    Start
    Aug 2012
    Primary Completion
    Oct 2012
    Completion
    Oct 2012
    NCT01919606
  • Phase 4
    Terminated

    A Health Economic Trial in Adult Patients Undergoing Laparoscopic Colectomy

    IV morphine sulfate or Sponsor-approved equivalent, EXPAREL

    Bowel Obstruction

    Enrollment
    122
    Start
    Dec 2011
    Primary Completion
    Sep 2012
    Completion
    Feb 2013
    NCT02058290
  • Phase 4
    Completed

    Pain Control in Bariatric Patients: EXPAREL(R) vs. the On-Q(R) Pain Ball

    EXPAREL, On-Q Pain Ball

    Obesity

    Enrollment
    101
    Start
    Nov 2012
    Primary Completion
    Mar 2013
    Completion
    Mar 2013
    NCT02142829
  • Phase 4
    Completed

    Pharmacokinetic Evaluation of EXPAREL in Adults Undergoing Tonsillectomy

    EXPAREL

    Pain

    Enrollment
    12
    Start
    Aug 2014
    Primary Completion
    Apr 2015
    Completion
    Jun 2015
    NCT02199574
  • Phase 4
    Completed

    EXPAREL Infiltration in Subjects Undergoing Femoral Nerve Block With Bupivacaine HCl for Total Knee Arthroplasty

    Bupivacaine FNB, EXPAREL Infiltration

    Pain

    Enrollment
    23
    Start
    Sep 2014
    Primary Completion
    Mar 2015
    Completion
    Mar 2015
    NCT02255500
  • Phase 4
    Completed

    Pharmacokinetics and Safety of Bupivacaine HCl Spinal Block and EXPAREL Local Infiltration in Total Knee Arthroplasty

    Bupivacaine SNB, EXPAREL Infiltration

    Pain

    Enrollment
    15
    Start
    Dec 2014
    Primary Completion
    Mar 2015
    Completion
    Mar 2015
    NCT02284386
  • Phase 4
    Terminated

    Evaluation of the Safety and Efficacy of EXPAREL When Administered Into the TAP in Subjects Undergoing Cesarean Section

    Intrathecal morphine injection, EXPAREL

    Pain

    Enrollment
    12
    Start
    May 2015
    Primary Completion
    Jun 2015
    Completion
    Jul 2015
    NCT02353754
  • Phase 4
    Completed

    Local Infiltration Analgesia With and Without EXPAREL Following Total Knee Arthroplasty

    EXPAREL, Bupivacaine

    Pain

    Enrollment
    140
    Start
    Apr 2016
    Primary Completion
    Feb 2017
    Completion
    Feb 2017
    NCT02713490
  • Phase 4
    Terminated

    Phase 4, Controlled Study in Adult Subjects Undergoing Primary, 1-2 Level, Open Lumbar Spinal Fusion Surgery

    EXPAREL and bupivacaine HCl, Bupivacaine HCl

    Postoperative Pain Management

    Enrollment
    38
    Start
    Feb 2017
    Primary Completion
    Oct 2017
    Completion
    Oct 2017
    NCT03015961
  • Phase 4
    Completed

    Evaluate the Safety and Efficacy of EXPAREL When Administered Via Infiltration Into the TAP vs. Bupivacaine Alone in Subjects Undergoing Elective C-Sections

    Exparel + Bupivacaine, Bupivacaine

    C-Section, Pain Management

    Enrollment
    186
    Start
    Jun 2017
    Primary Completion
    Nov 2018
    Completion
    Dec 2018
    NCT03176459
  • Phase 4
    Completed

    Efficacy and Safety of EXPAREL Versus Standard of Care (SoC) in Subjects Undergoing Elective Cesarean Section

    50 mcg Duramorph+ EXPAREL + multi-modal pain regimen, 150 mcg Duramorph + multi-modal pain regimen

    Elective Cesarean Section, Pain Management

    Enrollment
    167
    Start
    Mar 2019
    Primary Completion
    Jan 2020
    Completion
    Jan 2020
    NCT03853694
  • Phase 4
    Terminated

    Phase 4 Study in Adult Subjects Undergoing Posterior Lumbar Spine Surgeries

    EXPAREL and Bupivacaine, Standard of Care

    Postoperative Pain Management

    Enrollment
    65
    Start
    Jul 2019
    Primary Completion
    Aug 2020
    Completion
    Aug 2020
    NCT03927911
  • Phase 4
    Withdrawn

    EXPAREL Facia Iliaca Compartment Block for Intertrochanteric Hip Fracture

    EXPAREL, Ropivacaine

    Hip Fractures, Intertrochanteric Fractures

    Enrollment
    0
    Start
    Aug 2019
    Primary Completion
    May 2020est.
    Completion
    May 2020est.
    NCT03955458
  • Phase 3
    Completed

    Study to Evaluate Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy

    Bupivacaine HCl, SKY0402

    Hemorrhoids

    Enrollment
    204
    Start
    Aug 2008
    Primary Completion
    Feb 2009
    Completion
    Feb 2009
    NCT00744848
  • Phase 3
    Completed

    A Phase 3 Study to Evaluate the Safety and Efficacy of SKY0402 in Subjects Undergoing Total Knee Arthroplasty

    Bupivacaine HCl, SKY0402

    Postoperative Pain

    Enrollment
    245
    Start
    Aug 2008
    Primary Completion
    Jan 2009
    Completion
    Feb 2009
    NCT00745290

1-25 of 102

Search ClinicalTrials.gov for “Pacira BioSciences”